Semaglutide vs tirzepatide: the honest comparison.

Two molecules, one family

Semaglutide and tirzepatide are the two names that dominate every conversation about medical weight loss, and they are usually presented as rivals. It is more accurate to call them siblings. Both are once-weekly injectable peptides. Both are synthetic relatives of incretins, the gut hormones your body releases after a meal. Both were first developed for type 2 diabetes and then studied for weight, where the results reset expectations for the entire field. If you want the full tour of what these medications actually do inside the body, read the mechanism explainer first; this article assumes the short version.

Semaglutide is the elder sibling: a modified analog of the GLP-1 hormone itself, with the longer track record, the larger body of published evidence, and, as you will see below, one category of proof its rival has not matched yet. Tirzepatide is the newer arrival: a single engineered molecule that activates the GLP-1 receptor and a second incretin receptor called GIP at the same time.

You have probably heard both under their brand names. We are staying with the molecule names throughout, for a simple reason: the molecule is what the evidence measures, and the molecule is what a compounded preparation contains. The trial results in this article come from branded, FDA-approved products; compounded preparations of the same molecules are not FDA-approved, and results with them are not guaranteed to match.

One receptor or two

Semaglutide is a GLP-1 receptor agonist. In plain language, it is a long-lasting stand-in for a hormone you already make: it settles into GLP-1 receptors in the brain, the gut, and the pancreas and keeps them gently activated all week. The practical effects are quieter appetite, earlier fullness, a slower stomach, and steadier blood sugar.

Tirzepatide does all of that, and adds a second signal. GIP, glucose-dependent insulinotropic polypeptide, is another incretin hormone released after eating. Why stacking GIP on top of GLP-1 produces more weight loss is, candidly, still being worked out; the leading explanations involve additional effects on appetite circuits and on how the body handles energy, and some researchers believe the second signal also improves how well people tolerate the first. What is not in dispute is the outcome: in trial after trial, the dual agonist has produced larger average weight loss than the single one.

A fair way to hold this in your head: semaglutide is the proven original, tirzepatide is the same idea with a second engine. More engine is not automatically better for every person, which is where the rest of this article comes in.

The head to head numbers

For years the two molecules could only be compared across separate trials, with different participants and different designs, which is a polite way of saying they could not really be compared at all. That changed with SURMOUNT-5, a 72-week randomized trial that put them in the same room: 751 adults with obesity and without diabetes, assigned to the maximum tolerated dose of branded tirzepatide (10 mg or 15 mg weekly) or the maximum tolerated dose of branded semaglutide (1.7 mg or 2.4 mg weekly).

The secondary numbers point the same direction. Waist circumference fell by an average of 18.4 cm with tirzepatide versus 13.0 cm with semaglutide, and more tirzepatide participants reached each weight loss threshold the trial measured: 10%, 15%, 20%, and 25% of body weight.

Three honest caveats belong next to those figures. First, the trial was open label: participants and clinicians knew which medication they were on, which is a real, if modest, limitation. Second, both numbers are remarkable. A 13.7% average loss would have been the best result in the field only a few years ago; losing to tirzepatide does not make semaglutide weak. Third, averages flatten people. Plenty of individuals on semaglutide outperformed the tirzepatide average, and some on tirzepatide fell short of the semaglutide one. A trial tells you which way the odds lean, not what your body will do.

Where semaglutide wins: the heart evidence

If SURMOUNT-5 is tirzepatide's headline, SELECT is semaglutide's, and it is a different kind of headline. SELECT was not a weight trial. It enrolled 17,604 people aged 45 and older who had preexisting cardiovascular disease and overweight or obesity but no diabetes, gave half of them branded semaglutide 2.4 mg weekly and half placebo, and then simply followed them, for a mean of just under 40 months, to count heart attacks, strokes, and cardiovascular deaths.

The result: a first major cardiovascular event occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, a 20% relative reduction (hazard ratio 0.80). That is outcome evidence, proof that the medication changed what ultimately matters, not just what the scale says. Tirzepatide is being studied for the same kind of endpoints, but as of this writing it does not have a published equivalent of SELECT.

For most people choosing a treatment, this is a background fact. For a member with a history of heart disease, it can be the deciding one, and it is exactly the kind of factor a clinician weighs that a comparison chart cannot.

Side effects, compared

Here the two molecules are more alike than different. In SURMOUNT-5, the most common side effects in both groups were gastrointestinal: nausea, constipation, diarrhea. Most were mild to moderate, and most clustered during dose escalation, the weeks when the dose steps up to a new level and the body is still adjusting. That pattern repeats across the major trials of both molecules, and in those trials the large majority of participants completed treatment; only a small minority stopped because of side effects.

The practical translation: whichever molecule you start, expect the adjustment to be front-loaded, plan your eating around it, and tell your clinician early rather than late. A slower climb up the dose ladder solves more tolerability problems than switching molecules does. What that adjustment period actually feels like, week by week, is covered in the first 90 days guide, and both molecules share the serious-risk warnings you will find in the safety information on each treatment page, which you should read in full.

Cost and availability at Parke

Parke offers both molecules as compounded treatments prepared by vetted, US-licensed 503A pharmacies, prescribed only when a licensed clinician reviews your intake and decides treatment is appropriate. Compounded semaglutide starts at $133 per month. Compounded tirzepatide starts at $249 per month on the longest plan, and $299 on the monthly plan. In both cases the price is bundled: medication, clinician reviews, dose adjustments, unlimited messaging, and discreet shipping, with no charge at all if the clinician does not approve you. Multi-month plans lower the average monthly price, and the quarterly rhythm happens to match how this treatment actually unfolds; the case for quarterly refills makes that argument properly.

The gap between those two prices is not small over a year, and it deserves to be said plainly: if semaglutide does the job for you, the cheaper treatment that works is the better treatment. Paying more for tirzepatide buys you better average odds, not a guarantee, and a clinician can always revisit the choice later if your results argue for it.

Which one is right for you

This is the point where most comparison articles crown a winner. We are not going to, because the honest answer depends on inputs no article can see: your history, your budget, your goals, and how your body responds once treatment actually starts. What we can do is show you how our clinicians think about it.

The case that leans tirzepatide: you have a larger amount of weight to lose and the head to head averages matter to your goal, or you previously reached full titration on semaglutide, held it there for a fair stretch, and stalled short of where you and your clinician were aiming.

The case that leans semaglutide: a history of cardiovascular disease puts SELECT's outcome evidence on the scale, your budget makes the monthly difference meaningful over a year of treatment, or your goal is a moderate loss that semaglutide's averages already cover comfortably. Starting on the more affordable molecule and reassessing with your clinician is not settling. It is sequencing.

“The best molecule on paper is not automatically the best treatment for you. The right answer is the one your history, your budget, and your response all agree on, and you find it with a clinician, not a comparison chart.”

Dr. Priya Shah, MD · Endocrinology

One right answer: yours. That is not a dodge; it is the design. Your intake goes to a licensed clinician who knows what these trials say and, more usefully, knows what they cannot say about you. If you want a structured way to think through the inputs first, the two-minute treatment finder is built for exactly this fork.

Switching from semaglutide to tirzepatide

Members ask about this constantly, usually around a plateau, so let us set the expectations straight. Switching is routine and clinician-managed, and it is not a swap of numbers. The two molecules are dosed on entirely different scales, so there is no unit-for-unit conversion: your semaglutide dose does not translate into an equivalent tirzepatide dose. Your clinician retires one ladder and starts you on an appropriate step of the other, chosen from your history and tolerability rather than from arithmetic, and then titrates up from there. That usually means a stretch of weeks at doses below tirzepatide's full strength, and it can mean a brief return of the adjustment-period side effects while your body meets the new molecule. Why the ladder works that way is the subject of the titration explainer.

Just as important is when not to switch. A stall in the middle of the dose ladder is usually the schedule doing its job, not the molecule failing; the week 12 stall explains why the fix is most often the next planned step, not a new prescription. Switching earns its disruption when you have reached and held a full semaglutide dose, given it real time, and the results have genuinely flattened short of your goal, or when tolerability problems persist that a slower climb has not solved.

The bottom line

Tirzepatide produced meaningfully more average weight loss in the one large trial that compared the two molecules directly. Semaglutide costs less, has the longer track record, and is the only one of the pair with published proof that it prevents cardiovascular events in people with heart disease. Their side effect profiles are more alike than different. Those are the facts, and none of them contains your answer.

Your answer comes from putting those facts next to your history, your goal, and your budget, with a clinician who will still be there to adjust the plan when your body votes. That conversation starts with a private assessment, read by a licensed clinician within 24 hours, and it costs nothing unless you are approved.

This article is for general information and education. It is not medical advice and is not a substitute for care from a licensed clinician who knows your history. Trial results described here come from branded, FDA-approved products studied under clinical trial conditions. Compounded medications are prepared by state-licensed US compounding pharmacies and are not FDA-approved or evaluated; individual results vary and are never guaranteed. Treatment decisions, including any switch between molecules, are made only by a licensed clinician. Review the important safety information on each treatment page.